{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T19:26:03Z","timestamp":1792783563128,"version":"4.5.0"},"reference-count":81,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"name":"NIH and Industry"},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","award":["K23 HL144418"],"award-info":[{"award-number":["K23 HL144418"]}],"id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["annallergy.org","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Allergy, Asthma & Immunology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.anai.2019.10.016","type":"journal-article","created":{"date-parts":[[2019,10,23]],"date-time":"2019-10-23T19:56:27Z","timestamp":1571860587000},"page":"44-56","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":59,"title":["Asthma biologics"],"prefix":"10.1016","volume":"124","author":[{"given":"Ali","family":"Doroudchi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mohini","family":"Pathria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian D.","family":"Modena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.anai.2019.10.016_bib1","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1097\/MOO.0000000000000262","article-title":"Epidemiology of asthma","volume":"24","author":"Loftus","year":"2016","journal-title":"Curr Opin Otolaryngol Head Neck Surg"},{"issue":"Suppl 1","key":"10.1016\/j.anai.2019.10.016_bib2","first-page":"S7","article-title":"Epidemiology and economic burden of asthma","volume":"5","author":"Loftus","year":"2015","journal-title":"Int Forum Allergy Rhinol"},{"issue":"3","key":"10.1016\/j.anai.2019.10.016_bib3","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1513\/AnnalsATS.201703-259OC","article-title":"The economic burden of asthma in the United States, 2008\u20132013","volume":"15","author":"Nurmagambetov","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.anai.2019.10.016_bib4","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1183\/09031936.00202013","article-title":"International ERS\/ATS guidelines on definition, evaluation and treatment of severe asthma","volume":"43","author":"Chung","year":"2014","journal-title":"Eur Respir J"},{"issue":"2","key":"10.1016\/j.anai.2019.10.016_bib5","doi-asserted-by":"crossref","first-page":"126","DOI":"10.1111\/j.1398-9995.2006.01254.x","article-title":"Extent, patterns, and burden of uncontrolled disease in severe or difficult-to-treat asthma","volume":"62","author":"Sullivan","year":"2007","journal-title":"Allergy"},{"issue":"5","key":"10.1016\/j.anai.2019.10.016_bib6","doi-asserted-by":"crossref","first-page":"895","DOI":"10.1016\/j.jaci.2009.07.035","volume":"124","author":"Haselkorn","year":"2009","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2019.10.016_bib7","doi-asserted-by":"crossref","first-page":"716","DOI":"10.1038\/nm.2678","article-title":"Asthma phenotypes: the evolution from clinical to molecular approaches","volume":"18","author":"Wenzel","year":"2012","journal-title":"Nat Med"},{"issue":"1","key":"10.1016\/j.anai.2019.10.016_bib8","first-page":"1","article-title":"Group 2 innate lymphoid cells: new players in human allergic diseases","volume":"25","author":"Doherty","year":"2015","journal-title":"J\u00a0Invest Allergol Clin Immunol"},{"issue":"40","key":"10.1016\/j.anai.2019.10.016_bib9","doi-asserted-by":"crossref","first-page":"15858","DOI":"10.1073\/pnas.0707413104","article-title":"Genome-wide profiling identifies epithelial cell genes associated with asthma and with treatment response to corticosteroids","volume":"104","author":"Woodruff","year":"2007","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5","key":"10.1016\/j.anai.2019.10.016_bib10","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1164\/rccm.200903-0392OC","article-title":"T-helper type 2-driven inflammation defines major subphenotypes of asthma","volume":"180","author":"Woodruff","year":"2009","journal-title":"Am J Respir Crit Care Med"},{"issue":"12","key":"10.1016\/j.anai.2019.10.016_bib11","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1164\/rccm.201406-1099OC","article-title":"Gene expression in relation to exhaled nitric oxide identifies novel asthma phenotypes with unique biomolecular pathways","volume":"190","author":"Modena","year":"2014","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"10.1016\/j.anai.2019.10.016_bib12","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1016\/j.jaci.2015.02.039","article-title":"Correlation between CCL26 production by human bronchial epithelial cells and airway eosinophils: involvement in patients with severe eosinophilic asthma","volume":"136","author":"Larose","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"key":"10.1016\/j.anai.2019.10.016_bib13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1146\/annurev.immunol.24.021605.090720","article-title":"The eosinophil","volume":"24","author":"Rothenberg","year":"2006","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"10.1016\/j.anai.2019.10.016_bib14","doi-asserted-by":"crossref","first-page":"551","DOI":"10.1007\/s00441-016-2566-8","article-title":"Airway remodeling in asthma: what really matters","volume":"367","author":"Fehrenbach","year":"2017","journal-title":"Cell Tissue Res"},{"issue":"2","key":"10.1016\/j.anai.2019.10.016_bib15","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1164\/rccm.200409-1181PP","article-title":"Severe asthma in adults","volume":"172","author":"Wenzel","year":"2005","journal-title":"Am J Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.anai.2019.10.016_bib16","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.coph.2007.03.001","article-title":"TNF-alpha in asthma","volume":"7","author":"Berry","year":"2007","journal-title":"Curr Opin Pharmacol"},{"issue":"1","key":"10.1016\/j.anai.2019.10.016_bib17","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1016\/j.jaci.2007.10.028","article-title":"Targeting TNF-alpha: a novel therapeutic approach for asthma","volume":"121","author":"Brightling","year":"2008","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2019.10.016_bib18","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1084\/jem.20062211","article-title":"Thymic stromal lymphopoietin is released by human epithelial cells in response to microbes, trauma, or inflammation and potently activates mast cells","volume":"204","author":"Allakhverdi","year":"2007","journal-title":"J\u00a0Exp Med"},{"issue":"2","key":"10.1016\/j.anai.2019.10.016_bib19","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1016\/j.jcmgh.2017.01.005","article-title":"Thymic stromal lymphopoietin: to cut a long story short","volume":"3","author":"Tsilingiri","year":"2017","journal-title":"Cell Mol Gastroenterol Hepatol"},{"issue":"1","key":"10.1016\/j.anai.2019.10.016_bib20","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1097\/ACI.0000000000000133","article-title":"Recent advances in epithelium-derived cytokines (IL-33, IL-25, and thymic stromal lymphopoietin) and allergic inflammation","volume":"15","author":"Divekar","year":"2015","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2019.10.016_bib21","doi-asserted-by":"crossref","first-page":"741","DOI":"10.1165\/rcmb.2012-0304OC","article-title":"Transcription of interleukin-25 and extracellular release of the protein is regulated by allergen proteases in airway epithelial cells","volume":"49","author":"Kouzaki","year":"2013","journal-title":"Am J Respir Cell Mol Biol"},{"issue":"3","key":"10.1016\/j.anai.2019.10.016_bib22","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1016\/j.jaci.2009.12.935","article-title":"Increased IL-33 expression by epithelial cells in bronchial asthma","volume":"125","author":"Prefontaine","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"364","key":"10.1016\/j.anai.2019.10.016_bib23","article-title":"IL33: Roles in allergic inflammation and therapeutic perspectives","volume":"10","author":"Chan","year":"2019","journal-title":"Front Immunol"},{"issue":"9","key":"10.1016\/j.anai.2019.10.016_bib24","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1084\/jem.20051135","article-title":"TSLP-activated dendritic cells induce an inflammatory T helper type 2 cell response through OX40 ligand","volume":"202","author":"Ito","year":"2005","journal-title":"J\u00a0Exp Med"},{"issue":"3","key":"10.1016\/j.anai.2019.10.016_bib25","first-page":"CD003559","article-title":"Anti-IgE for chronic asthma","author":"Walker","year":"2003","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"10.1016\/j.anai.2019.10.016_bib26","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1185\/030079903125002171","article-title":"Pharmacodynamics of omalizumab: implications for optimised dosing strategies and clinical efficacy in the treatment of allergic asthma","volume":"19","author":"Hochhaus","year":"2003","journal-title":"Curr Med Res Opin"},{"issue":"1","key":"10.1016\/j.anai.2019.10.016_bib27","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/S0091-6749(97)70202-1","article-title":"Use of an anti-IgE humanized monoclonal antibody in ragweed-induced allergic rhinitis","volume":"100","author":"Casale","year":"1997","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2019.10.016_bib28","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1038\/nm.2755","article-title":"IgE and mast cells in allergic disease","volume":"18","author":"Galli","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.anai.2019.10.016_bib29","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1016\/j.trsl.2016.02.011","article-title":"Emerging concepts: mast cell involvement in allergic diseases","volume":"174","author":"Modena","year":"2016","journal-title":"Transl Res"},{"key":"10.1016\/j.anai.2019.10.016_bib30","doi-asserted-by":"crossref","first-page":"49","DOI":"10.2147\/JAA.S14520","article-title":"Update on optimal use of omalizumab in management of asthma","volume":"4","author":"Pelaia","year":"2011","journal-title":"J\u00a0Asthma Allergy"},{"issue":"2","key":"10.1016\/j.anai.2019.10.016_bib31","doi-asserted-by":"crossref","first-page":"184","DOI":"10.1067\/mai.2001.117880","article-title":"Omalizumab, anti-IgE recombinant humanized monoclonal antibody, for the treatment of severe allergic asthma","volume":"108","author":"Busse","year":"2001","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2019.10.016_bib32","doi-asserted-by":"crossref","first-page":"1476","DOI":"10.1016\/j.jaci.2015.09.008","article-title":"Preseasonal treatment with either omalizumab or an inhaled corticosteroid boost to prevent fall asthma exacerbations","volume":"136","author":"Teach","year":"2015","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"2","key":"10.1016\/j.anai.2019.10.016_bib33","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.jaci.2012.05.023","article-title":"Innate immune responses to rhinovirus are reduced by the high-affinity IgE receptor in allergic asthmatic children","volume":"130","author":"Durrani","year":"2012","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2019.10.016_bib34","doi-asserted-by":"crossref","first-page":"573","DOI":"10.1164\/rccm.200307-1004OC","article-title":"Sputum CD34+IL-5Ralpha+ cells increase after allergen: evidence for in situ eosinophilopoiesis","volume":"169","author":"Dorman","year":"2004","journal-title":"Am J Respir Crit Care Med"},{"issue":"8","key":"10.1016\/j.anai.2019.10.016_bib35","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1111\/j.1398-9995.2004.00469.x","article-title":"Cytokine-regulated accumulation of eosinophils in inflammatory disease","volume":"59","author":"Lampinen","year":"2004","journal-title":"Allergy"},{"key":"10.1016\/j.anai.2019.10.016_bib36","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2147\/JAA.S78049","article-title":"Benralizumab: a unique IL-5 inhibitor for severe asthma","volume":"9","author":"Tan","year":"2016","journal-title":"J\u00a0Asthma Allergy"},{"issue":"6","key":"10.1016\/j.anai.2019.10.016_bib37","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1016\/j.jaci.2010.04.004","article-title":"MEDI-563, a humanized anti-IL-5 receptor alpha mAb with enhanced antibody-dependent cell-mediated cytotoxicity function","volume":"125","author":"Kolbeck","year":"2010","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"Suppl 2","key":"10.1016\/j.anai.2019.10.016_bib38","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1590\/S0074-02761997000800012","article-title":"IL-5 and IL-5 receptor in asthma","volume":"92","author":"Kotsimbos","year":"1997","journal-title":"Mem Inst Oswaldo Cruz"},{"issue":"22","key":"10.1016\/j.anai.2019.10.016_bib39","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1056\/NEJM199805283382206","article-title":"Eosinophilia","volume":"338","author":"Rothenberg","year":"1998","journal-title":"N\u00a0Engl J Med"},{"issue":"6","key":"10.1016\/j.anai.2019.10.016_bib40","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1097\/ACI.0000000000000108","article-title":"Anti-interleukin 4 and 13 for asthma treatment in the era of endotypes","volume":"14","author":"Kau","year":"2014","journal-title":"Curr Opin Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2019.10.016_bib41","doi-asserted-by":"crossref","first-page":"736","DOI":"10.1038\/nm.2754","article-title":"Therapies for allergic inflammation: refining strategies to induce tolerance","volume":"18","author":"Akdis","year":"2012","journal-title":"Nat Med"},{"issue":"2","key":"10.1016\/j.anai.2019.10.016_bib42","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1159\/000447692","article-title":"A\u00a0critical evaluation of anti-IL-13 and anti-IL-4 strategies in severe asthma","volume":"170","author":"Bagnasco","year":"2016","journal-title":"Int Arch Allergy Immunol"},{"key":"10.1016\/j.anai.2019.10.016_bib43","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1038\/nrd4624","article-title":"Targeting key proximal drivers of type 2 inflammation in disease","volume":"15","author":"Gandhi","year":"2015","journal-title":"Nature Reviews Drug Discovery"},{"issue":"2","key":"10.1016\/j.anai.2019.10.016_bib44","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1183\/09031936.01.00092101","article-title":"The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics","volume":"18","author":"Sol\u00e8r","year":"2001","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.anai.2019.10.016_bib45","doi-asserted-by":"crossref","first-page":"877","DOI":"10.1002\/alr.21213","article-title":"Staphylococcus aureus biofilm activates the nucleotide-binding oligomerization domain containing 2 (Nod2) pathway and proinflammatory factors on a human sinonasal explant model","volume":"3","author":"Cantero","year":"2013","journal-title":"Int Forum Allergy Rhinol"},{"issue":"2","key":"10.1016\/j.anai.2019.10.016_bib46","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1111\/all.13302","article-title":"Response to omalizumab using patient enrichment criteria from trials of novel biologics in asthma","volume":"73","author":"Casale","year":"2018","journal-title":"Allergy"},{"issue":"1","key":"10.1016\/j.anai.2019.10.016_bib47","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jaip.2018.04.043","article-title":"Omalizumab effectiveness by biomarker status in patients with asthma: evidence from PROSPERO, a prospective real-world study","volume":"7","author":"Casale","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"5","key":"10.1016\/j.anai.2019.10.016_bib48","doi-asserted-by":"crossref","first-page":"1702523","DOI":"10.1183\/13993003.02523-2017","article-title":"Omalizumab effectiveness in patients with severe allergic asthma according to blood eosinophil count: the STELLAIR study","volume":"51","author":"Humbert","year":"2018","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.anai.2019.10.016_bib49","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1111\/j.1398-9995.2004.00772.x","article-title":"Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE","volume":"60","author":"Humbert","year":"2005","journal-title":"Allergy"},{"issue":"9","key":"10.1016\/j.anai.2019.10.016_bib50","doi-asserted-by":"crossref","first-page":"573","DOI":"10.7326\/0003-4819-154-9-201105030-00002","article-title":"Omalizumab in severe allergic asthma inadequately controlled with standard therapy: a randomized trial","volume":"154","author":"Hanania","year":"2011","journal-title":"Ann Intern Med"},{"issue":"8","key":"10.1016\/j.anai.2019.10.016_bib51","doi-asserted-by":"crossref","first-page":"804","DOI":"10.1164\/rccm.201208-1414OC","article-title":"Exploring the effects of omalizumab in allergic asthma: an analysis of biomarkers in the EXTRA study","volume":"187","author":"Hanania","year":"2013","journal-title":"Am J Respir Crit Care Med"},{"key":"10.1016\/j.anai.2019.10.016_bib52","series-title":"Omalizumab for asthma in adults and children","author":"Normansell","year":"2019"},{"issue":"9842","key":"10.1016\/j.anai.2019.10.016_bib53","doi-asserted-by":"crossref","first-page":"651","DOI":"10.1016\/S0140-6736(12)60988-X","article-title":"Mepolizumab for severe eosinophilic asthma (DREAM): a multicentre, double-blind, placebo-controlled trial","volume":"380","author":"Pavord","year":"2012","journal-title":"The Lancet"},{"issue":"13","key":"10.1016\/j.anai.2019.10.016_bib54","doi-asserted-by":"crossref","first-page":"1198","DOI":"10.1056\/NEJMoa1403290","article-title":"Mepolizumab treatment in patients with severe eosinophilic asthma","volume":"371","author":"Ortega","year":"2014","journal-title":"N\u00a0Engl J Med"},{"issue":"13","key":"10.1016\/j.anai.2019.10.016_bib55","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa1403291","article-title":"Oral glucocorticoid-sparing effect of mepolizumab in eosinophilic asthma","volume":"371","author":"Bel","year":"2014","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2019.10.016_bib56","first-page":"Cd010834","article-title":"Mepolizumab versus placebo for asthma","volume":"7","author":"Powell","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.1016\/j.anai.2019.10.016_bib57","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1016\/S2213-2600(15)00042-9","article-title":"Reslizumab for inadequately controlled asthma with elevated blood eosinophil counts: results from two multicentre, parallel, double-blind, randomised, placebo-controlled, phase 3 trials","volume":"3","author":"Castro","year":"2015","journal-title":"Lancet Respir Med"},{"issue":"11","key":"10.1016\/j.anai.2019.10.016_bib58","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1016\/S2213-2600(14)70201-2","article-title":"Benralizumab, an anti-interleukin 5 receptor alpha monoclonal antibody, versus placebo for uncontrolled eosinophilic asthma: a phase 2b randomised dose-ranging study","volume":"2","author":"Castro","year":"2014","journal-title":"Lancet Respir Med"},{"issue":"10056","key":"10.1016\/j.anai.2019.10.016_bib59","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1016\/S0140-6736(16)31322-8","article-title":"Benralizumab, an anti-interleukin-5 receptor alpha monoclonal antibody, as add-on treatment for patients with severe, uncontrolled, eosinophilic asthma (CALIMA): a randomised, double-blind, placebo-controlled phase 3 trial","volume":"388","author":"FitzGerald","year":"2016","journal-title":"Lancet"},{"issue":"10056","key":"10.1016\/j.anai.2019.10.016_bib60","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1016\/S0140-6736(16)31324-1","article-title":"Efficacy and safety of benralizumab for patients with severe asthma uncontrolled with high-dosage inhaled corticosteroids and long-acting beta2-agonists (SIROCCO): a randomised, multicentre, placebo-controlled phase 3 trial","volume":"388","author":"Bleecker","year":"2016","journal-title":"Lancet"},{"issue":"25","key":"10.1016\/j.anai.2019.10.016_bib61","doi-asserted-by":"crossref","first-page":"2448","DOI":"10.1056\/NEJMoa1703501","article-title":"Oral glucocorticoid-sparing effect of benralizumab in severe asthma","volume":"376","author":"Nair","year":"2017","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.anai.2019.10.016_bib62","article-title":"Anti-IL5 therapies for asthma","volume":"9","author":"Farne","year":"2017","journal-title":"Cochrane Database Syst Rev"},{"issue":"26","key":"10.1016\/j.anai.2019.10.016_bib63","doi-asserted-by":"crossref","first-page":"2455","DOI":"10.1056\/NEJMoa1304048","article-title":"Dupilumab in persistent asthma with elevated eosinophil levels","volume":"368","author":"Wenzel","year":"2013","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.anai.2019.10.016_bib64","doi-asserted-by":"crossref","first-page":"2486","DOI":"10.1056\/NEJMoa1804092","article-title":"Dupilumab efficacy and safety in moderate-to-severe uncontrolled asthma","volume":"378","author":"Castro","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"26","key":"10.1016\/j.anai.2019.10.016_bib65","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N\u00a0Engl J Med"},{"issue":"4","key":"10.1016\/j.anai.2019.10.016_bib66","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1016\/j.chest.2016.03.018","article-title":"Phase 3 study of reslizumab in patients with poorly controlled asthma: effects across a broad range of eosinophil counts","volume":"150","author":"Corren","year":"2016","journal-title":"Chest"},{"issue":"1","key":"10.1016\/j.anai.2019.10.016_bib67","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1016\/S2213-2600(18)30406-5","article-title":"Long-term safety and efficacy of benralizumab in patients with severe, uncontrolled asthma: 1-year results from the BORA phase 3 extension trial","volume":"7","author":"Busse","year":"2019","journal-title":"Lancet Respir Med"},{"issue":"8","key":"10.1016\/j.anai.2019.10.016_bib68","doi-asserted-by":"crossref","first-page":"1779","DOI":"10.1002\/lary.25318","article-title":"The predictive value of the preoperative Sinonasal Outcome Test-22 score in patients undergoing endoscopic sinus surgery for chronic rhinosinusitis","volume":"125","author":"Hopkins","year":"2015","journal-title":"Laryngoscope"},{"issue":"3","key":"10.1016\/j.anai.2019.10.016_bib69","doi-asserted-by":"crossref","first-page":"921","DOI":"10.1016\/j.jaci.2013.11.026","article-title":"Outcomes after cessation of mepolizumab therapy in severe eosinophilic asthma: a 12-month follow-up analysis","volume":"133","author":"Haldar","year":"2014","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2019.10.016_bib70","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1016\/S2213-2600(17)30344-2","article-title":"Predictors of enhanced response with benralizumab for patients with severe asthma: pooled analysis of the SIROCCO and CALIMA studies","volume":"6","author":"FitzGerald","year":"2018","journal-title":"Lancet Respir Med"},{"key":"10.1016\/j.anai.2019.10.016_bib72","doi-asserted-by":"crossref","DOI":"10.1002\/ppul.24508","article-title":"Subcutaneous mepolizumab in children aged 6 to 11 years with severe eosinophilic asthma","author":"Gupta","year":"2019","journal-title":"Pediatr Pulmonol"},{"issue":"5","key":"10.1016\/j.anai.2019.10.016_bib73","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1016\/j.jaci.2018.09.033","article-title":"Assessment of the long-term safety of mepolizumab and durability of clinical response in patients with severe eosinophilic asthma","volume":"143","author":"Khatri","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"6","key":"10.1016\/j.anai.2019.10.016_bib74","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1016\/j.jaip.2017.08.024","article-title":"Long-term safety and efficacy of reslizumab in patients with eosinophilic asthma","volume":"5","author":"Murphy","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol Pract"},{"issue":"3","key":"10.1016\/j.anai.2019.10.016_bib75","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/crj.12998","article-title":"Disseminated herpes zoster following treatment with benralizumab","volume":"13","author":"Mishra","year":"2019","journal-title":"Clin Respir J"},{"key":"10.1016\/j.anai.2019.10.016_bib76","series-title":"The Global Asthma Report 2014","year":"2014"},{"key":"10.1016\/j.anai.2019.10.016_bib77","doi-asserted-by":"crossref","DOI":"10.1016\/j.jaci.2019.08.005","article-title":"Long-term safety and pharmacodynamics of mepolizumab in children with severe asthma with an eosinophilic phenotype","author":"Gupta","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"1","key":"10.1016\/j.anai.2019.10.016_bib78","doi-asserted-by":"crossref","first-page":"110","DOI":"10.4161\/mabs.4.1.18349","article-title":"Tolerability, pharmacokinetics and pharmacodynamics of CMAB007, a humanized anti-immunoglobulin E monoclonal antibody, in healthy Chinese subjects","volume":"4","author":"Zhou","year":"2012","journal-title":"MAbs"},{"issue":"6","key":"10.1016\/j.anai.2019.10.016_bib79","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1007\/s40259-016-0199-9","article-title":"Monoclonal antibody and fusion protein biosimilars across therapeutic areas: a systematic review of published evidence","volume":"30","author":"Jacobs","year":"2016","journal-title":"BioDrugs"},{"issue":"2","key":"10.1016\/j.anai.2019.10.016_bib80","doi-asserted-by":"crossref","first-page":"AB422","DOI":"10.1016\/j.jaci.2018.12.948","article-title":"Efficacy and safety of dupilumab in patients with chronic rhinosinusitis with nasal polyps: results from the randomized phase 3 sinus-24 study","volume":"143","author":"Han","year":"2019","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"5","key":"10.1016\/j.anai.2019.10.016_bib81","doi-asserted-by":"crossref","first-page":"989","DOI":"10.1016\/j.jaci.2011.07.056","article-title":"Mepolizumab, a humanized anti\u2013IL-5 mAb, as a treatment option for severe nasal polyposis","volume":"128","author":"Gevaert","year":"2011","journal-title":"J\u00a0Allergy Clin Immunol"},{"issue":"4","key":"10.1016\/j.anai.2019.10.016_bib82","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1016\/j.jaci.2017.05.044","article-title":"Reduced need for surgery in severe nasal polyposis with mepolizumab: randomized trial","volume":"140","author":"Bachert","year":"2017","journal-title":"J\u00a0Allergy Clin Immunol"}],"container-title":["Annals of Allergy, Asthma & Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619313018?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1081120619313018?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T13:22:05Z","timestamp":1761052925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1081120619313018"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":81,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S1081120619313018"],"URL":"https:\/\/doi.org\/10.1016\/j.anai.2019.10.016","relation":{},"ISSN":["1081-1206"],"issn-type":[{"value":"1081-1206","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Asthma biologics","name":"articletitle","label":"Article Title"},{"value":"Annals of Allergy, Asthma & Immunology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.anai.2019.10.016","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 American College of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}